Perspectives on the Unmet Need in the Treatment of Major Depressive Disorder: Results From A Patient Survey

Abstract: Background: Major depressive disorder (MDD) is a common brain health disorder that affects at least 1 in 5 individuals in the United States (US) during their lifetime. Adults with MDD were surveyed to rate the importance of desirable attributes associated with a new therapy for MDD. Methods: This was a cross-sectional survey of adults in the US who self-reported a diagnosis of MDD. Participants were recruited by the Depression and Bipolar Support Alliance or patient panel. Participants reported previous or current treatment with ≥ 1 antidepressant (ADT) for ≥ 2 weeks. Data were collected between May and November 2021. Results: Of the 715 people who completed the survey, most were female (78%), white (86%), and employed (53%). Most participants (82%) were taking an ADT for ≥ 6 months. Participants rated the following attributes of a new medication for MDD as “very important” or “extremely important”: (1) prevents depression from coming back, 91%; (2) has fewer side effects, 90%; (3) has a body of research that shows it to be safe and effective, 90%; (4) can be discontinued without experiencing withdrawal symptoms, 84%; (5) works quickly to improve most depression symptoms, 68%; and (6) can be prescribed again for a 2-week period if depressive symptoms come back, 57%. Conclusions: Results suggest a safe and effective treatment that prevents the recurrence of depression, acts quickly, has fewer side effects and no risk of withdrawal symptoms, and has a flexible regimen for repeat treatment, is preferred.Short Description: This was a cross-sectional survey of adults in the US who self-reported a diagnosis of MDD and reported previous or current treatment with antidepressant (Nf715). Participants were recruited by the Depression and Bipolar Support Alliance or patient panel. Results suggest a safe and effective treatment that prevents the recurrence of depression, acts quickly, has fewer side effects and no risk of withdrawal symptoms, and has a flexible regimen for repeat treatment, is preferred.Name of Sponsoring Organization(s): This study was funded by Sage Therapeutics, Inc. and Biogen Inc. Medical writing support was provided by RTI Health Solutions and funded by Sage Therapeutics, Inc and Biogen Inc.